Wird geladen...
Mortality Benefit of Alirocumab: A Bayesian Perspective
BACKGROUND: The ODYSSEY OUTCOMES (Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome) trial demonstrated that alirocumab reduced major cardiovascular events. However, because of the hierarchical testing strategy used for the multiple outcomes examined, the observed reduction in all...
Gespeichert in:
| Veröffentlicht in: | J Am Heart Assoc |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
John Wiley and Sons Inc.
2019
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6818032/ https://ncbi.nlm.nih.gov/pubmed/31599200 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.119.013170 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|